Pasithea Therapeutics Corp. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Pasithea Therapeutics performed this year. I’ve skipped the dense financial jargon so you can decide if this company fits your investment strategy.

1. What does this company do?

Pasithea is a biotech company in the research phase. They do not sell any products yet, so they have no revenue. They focus on creating small-molecule drugs to treat cancer and genetic disorders.

Their main project is PAS-004, a next-generation drug for neurofibromatosis type 1 (NF1) and solid tumors. Older drugs in this category often cause harsh side effects like rashes and diarrhea, leading patients to stop treatment. PAS-004 uses a unique chemical structure designed to be more stable and selective, which should help patients stay on the medication longer.

2. How is the drug testing going?

This is the most important part of their story.

• Safety Wins: In their early trials, 34 patients showed no serious side effects. This is a positive sign for a drug meant to be taken over a long period.
• Better Design: Their drug’s shape helps it resist breaking down too quickly in the liver. This keeps drug levels steady in the body, which may reduce side effects.
• New Trials: In May 2025, they started a trial for adults with NF1. They are testing patients in the U.S., Australia, and South Korea to speed up data collection.

3. Financial health

Since they are still researching, the company loses money every quarter.

• Strategic Pivot: They stopped their ALS program to save money. Now, they are putting all their resources into PAS-004 to make their cash last longer.
• Funding: They have about $16.4 million in cash. Management notes they will need to raise more money to reach their goals. This will likely mean issuing more shares, which reduces your ownership percentage in the company.

4. Key risks

• The "All-in" Gamble: By focusing only on PAS-004, the company has no backup plans. If this drug fails, the company has no other programs to support its value.
• Long Timeline: They do not expect to finish their main study until 2028. This long wait exposes you to risks like regulatory delays or changes in the market.
• Competition: They are entering a crowded market. To succeed, Pasithea must prove their drug is better or safer than established treatments, which is a very high bar.

5. Future outlook

The company is moving from discovery to clinical testing. Upcoming goals include switching from capsules to tablets for easier manufacturing and studying how food affects drug absorption.

Note: This is a high-risk, high-reward investment. You are betting on the science, not on current profits. Before investing, consider whether you are comfortable with a company that has no revenue, a long path to potential approval, and a need to raise more capital in the future.